Brief: Neurometrix Announces That Top-Line Results From A Randomized Controlled Trial Of Quell® For Treatment Of Fibromyalgia To Be Presented At Two Upcoming Pain Medicine Conferences
09/06/2021 13:44
June 9 (Reuters) - NeuroMetrix Inc NURO.O :
* NEUROMETRIX ANNOUNCES THAT TOP-LINE RESULTS FROM A
RANDOMIZED
CONTROLLED TRIAL OF QUELL® FOR TREATMENT OF FIBROMYALGIA TO BE
PRESENTED AT TWO UPCOMING PAIN MEDICINE CONFERENCES
Source text for Eikon: ID:nGNX8XtV9P
Further company coverage: NURO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NeuroMetrix
See all newsBrief: Neurometrix To Be Acquired By Electrocore
Brief: Neurometrix Reiterates Its Review Of Strategic Alternatives
Brief: NeuroMetrix Announces Steps Taken To Enhance Shareholder Value
Brief: Ephraim Fields Reports 9.3% Stake In Neurometrix, Inc. As Of Feb 23, 2024 - SEC Filing
Brief: RS Fund Reports 14.4% Stake In Neurometrix Inc As Of Feb 13